Abstract
Background: Congenital hypothyroidism (CH) is one of the most common preventative evolutionary disorders in newborns and children, which, if not treated promptly, leads to mental retardation and developmental disorders. 
Objective: The purpose of this study was to assess the developmental status of 3 to 5-year-old children with congenital hypothyroidism treated with levothyroxine in Ardabil city in Northwest Iran. 
Methods: In a descriptive cross-sectional study, 78 infants (44 boys and 34 girls) with congenital hypothyroidism under treatment with levothyroxine who referred to Ardabil city health centers during 2013-2018 were evaluated by an Ages and Stages Questionnaire (ASQ) for their developmental status. 
Results: In total, 32 (41%) were impaired and 46 (59%) were healthy according to the ASQ. Of those, 11 children (14.1%) had temporary congenital hypothyroidism. There was no significant difference in terms of height, weight, birth weight, maternal age, number of tests performed each year, average TSH (Thyroid-stimulating Hormone) in the first year of treatment, gender, place of residence, education and parental relationship between two impaired and healthy children. There was a significant relation between number of visits by doctor (p=0.02), age at diagnosis (p=0.001) and age at treatment time (p=0.003), initial dose of levothyroxine (p=0.02) with developmental status of children based on ASQ results. 
Conclusion: According to the findings of this study, it can be concluded that neonatal screening is one of the most successful health-system programs in the country, and the detection and initiation of hypothyroidism in neonates as soon as possible leads to a reduction in developmental disorder in them.
 
Keywords: Children, Congenital Hypothyroidism, Development, Thyroid

 

» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7674

Current Issue

Volume 12, Issue 3, July-September 2020

 


 

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.

To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


 

The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


 

TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:


Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: